Dr. Lyons will lead GGC’s efforts in clinical, diagnostic, research, and educational initiatives to advance the field of medical genomics and therapeutics.
GREENWOOD, S.C. – GGC has named Michael Lyons, MD, current Director of Clinical Services, as the new Ravenel Boykin Curry Chair in Translational Genomics and Therapeutics.
Dr. Lyons will lead the Precision Medicine Initiative at GGC to identify how research discoveries can improve the care of all patients. As the new endowed chair, Dr. Lyons will contribute to GGC’s clinical, diagnostic, research, and educational initiatives by overseeing the Center’s Genomic Discovery Program (GDP) and providing leadership direction for clinical trials to improve and repurpose existing treatments. He will also seek to extend GGC’s sphere of influence, collaborate with healthcare professionals to develop personalized treatments, and facilitate research initiatives that bridge the gap between basic science and clinical applications.
“We are committed to finding answers for patients with undiagnosed genetic conditions, expanding care options, and delivering personalized treatments,” said Dr. Lyons, who oversees patient care across GGC’s five offices in his current role. “Moving forward, my vision is to expand GGC’s influence throughout the genetics community to serve more patients through improved genetic testing and therapeutic advances.”
Dr. Lyons, who joined GGC in 2005, brings years of experience and passion to his new role as the Ravenel Boykin Curry Chair. A graduate of Tufts University School of Medicine, he is a distinguished clinical geneticist with experience in telehealth, dysmorphology, single gene disorders, genetics education, and treatment of genetic disorders. Lyons is board-certified by the American Board of Pediatrics and the American Board of Medical Genetics and Genomics.
“With a distinguished career of providing high-quality, compassionate patient care, Dr. Lyons is the perfect person to fill the Ravenel Boykin Curry Chair. He is dedicated to the patients and families he serves and has a strong commitment to finding accurate diagnoses and effective treatments that will improve their quality of life. We know the future is bright with Dr. Lyons stepping forward to fill this important role,” said Dr. Steve Skinner, President and CEO of GGC.
The Ravenel Boykin Curry Chair in Translational Genomics and Therapeutics was established in 2012 by Ravenel and Beth Curry through their Foundation in honor of Ravenel’s father, Ravenel Boykin Curry, Jr. who was a cornerstone of the Greenwood Community, a founding member of the GGC Board of Directors, and an active participant in every phase of the Center’s early development.
